Cornell Preprint: Interactomics Screen Reveals New Kratom Alkaloid Biosynthetic Pathways

Why it matters

A new Cornell University preprint reports the discovery of previously unknown alkaloid biosynthetic pathways in kratom using a yeast-based protein interaction screen. The work identifies six novel enzymes and two new alkaloids, advancing the basic science that could eventually enable pharmaceutical synthesis of kratom-derived compounds.

The big picture

Understanding how kratom produces its pharmacologically active alkaloids — including mitragynine — is a prerequisite for developing synthetic or semi-synthetic derivatives with precisely tuned therapeutic profiles. Cornell's earlier work (April 2026) completed the full biosynthetic pathway in yeast; this follow-on study digs deeper into the plant's enzymatic machinery using an interactomics approach, finding even more complexity in the pathway.

Key findings

• Researchers used a large-scale yeast-based protein-protein interaction (PPI) screen focused on a key kratom enzyme (strictosidine beta-D-glucosidase, SGD)
• Six novel medium-chain dehydrogenase/reductase (MDR) enzymes were identified as high-confidence SGD interaction partners
• All six MsMDRs produce a new monoterpene indole alkaloid (MIA) the team named 'charlamine'
• One MsMDR also converts another intermediate into a second new alkaloid, 'vallesiachotaminol'
• A biosynthetic gene cluster containing a downstream esterase enzyme was also discovered, indicating the pathway is more complex than previously known
• Funded by NIH (R01AT012633) and the National Science Foundation

What they say

The Cornell research team, led by Sijin Li, states the findings 'demonstrate the utility of interactomics-driven plant pathway discovery,' presenting a scalable method for mapping hidden biosynthetic routes in pharmacologically important plants.

Bottom line

Cornell researchers have discovered two entirely new kratom alkaloids and six previously unknown enzymes in the plant's biosynthetic pathway — advancing the foundational science needed to engineer safer, pharmaceutical-grade kratom-derived compounds.